BEAT vs. ANIK, DRTS, RCEL, LUNG, CATX, ARAY, OBIO, SKIN, UTMD, and KRMD
Should you be buying BioTelemetry stock or one of its competitors? The main competitors of BioTelemetry include Anika Therapeutics (ANIK), Alpha Tau Medical (DRTS), AVITA Medical (RCEL), Pulmonx (LUNG), Perspective Therapeutics (CATX), Accuray (ARAY), Orchestra BioMed (OBIO), Beauty Health (SKIN), Utah Medical Products (UTMD), and KORU Medical Systems (KRMD). These companies are all part of the "surgical & medical instruments" industry.
BioTelemetry vs.
BioTelemetry (NASDAQ:BEAT) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, community ranking, media sentiment, institutional ownership, dividends, valuation and risk.
BioTelemetry has a beta of -0.71, meaning that its stock price is 171% less volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500.
BioTelemetry received 88 more outperform votes than Anika Therapeutics when rated by MarketBeat users. However, 64.33% of users gave Anika Therapeutics an outperform vote while only 63.37% of users gave BioTelemetry an outperform vote.
BioTelemetry presently has a consensus price target of $8.00, suggesting a potential upside of 236.56%. Anika Therapeutics has a consensus price target of $24.50, suggesting a potential upside of 37.33%. Given BioTelemetry's stronger consensus rating and higher possible upside, analysts clearly believe BioTelemetry is more favorable than Anika Therapeutics.
BioTelemetry has higher earnings, but lower revenue than Anika Therapeutics. BioTelemetry is trading at a lower price-to-earnings ratio than Anika Therapeutics, indicating that it is currently the more affordable of the two stocks.
BioTelemetry has a net margin of 0.00% compared to Anika Therapeutics' net margin of -59.40%. Anika Therapeutics' return on equity of -2.22% beat BioTelemetry's return on equity.
In the previous week, BioTelemetry had 2 more articles in the media than Anika Therapeutics. MarketBeat recorded 2 mentions for BioTelemetry and 0 mentions for Anika Therapeutics. BioTelemetry's average media sentiment score of 0.00 equaled Anika Therapeutics'average media sentiment score.
7.8% of BioTelemetry shares are owned by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are owned by institutional investors. 20.9% of BioTelemetry shares are owned by insiders. Comparatively, 7.9% of Anika Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
BioTelemetry beats Anika Therapeutics on 8 of the 15 factors compared between the two stocks.
Get BioTelemetry News Delivered to You Automatically
Sign up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioTelemetry Competitors List
Related Companies and Tools
This page (NASDAQ:BEAT) was last updated on 2/5/2025 by MarketBeat.com Staff
